Recurrent Pericarditis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Recurrent Pericarditis Emerging Therapy and TPP Insights

Thelansis’s “Recurrent Pericarditis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent Pericarditis Overview

Recurrent Pericarditis, a syndrome characterized by the reappearance of pericardial inflammation symptoms after a symptom-free interval of 4–6 weeks following an acute pericarditis episode, is a significant medical concern. Various factors, including infections and autoimmune responses, can trigger this condition. Recurrent pericarditis symptoms encompass a dull ache, pressure, or stabbing chest pain that intensifies when coughing, taking deep breaths, or lying down. This pain, often mistaken for a heart attack, is alleviated by sitting up and leaning forward. Patients may also experience shortness of breath or difficulty breathing. This syndrome is the most challenging complication of acute Pericarditis, with 20% to 50% of patients experiencing recurrence within 18 months of the initial acute pericarditis episode. This can result in repeated hospitalizations and increased treatment costs. In approximately 85% of cases, the etiology remains idiopathic as it cannot be identified using standard laboratory techniques. Systemic diseases, including lupus erythematosus, Sjögren syndrome, rheumatic arthritis, scleroderma, and systemic vasculitis, among others, are often responsible for many recurrent cases. These diseases are well-known manifestations of recurrent Pericarditis.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Recurrent Pericarditis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025